The GLP-1 revolution is quietly continuing even as investor interest has moved on to more timely topics. One of the best ways to access the fast-growing weight loss drug space is via makers like Novo Nordisk (NYSE: NVO) or Eli Lilly (NYSE: LLY), the leading companies responsible for developing and manufacturing products like Ozempic and Zepbound.
There are, of course, less direct ways that investors can benefit from the GLP-1 rush as well. The prospect of the market tripling in size in the coming years has enticed a host of other drug developers to work toward their own offerings, and a number of up-and-coming pharma firms may be worth watching—or investors can look at dedicated exchange-traded funds (ETFs) like the Roundhill GLP-1 & Weight Loss ETF (NASDAQ: OZEM) for a broader view.
